Jiangsu Sihuan Bioengineering Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2020
August 28, 2020 at 01:21 pm IST
Share
Jiangsu Sihuan Bioengineering Co. Ltd. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was CNY 236.569 million compared to CNY 173.982 million a year ago. Operating income was CNY 9.405 million compared to operating loss of CNY 11.068 million a year ago. Net income was CNY 6.296 million compared to net loss of CNY 9.373 million a year ago. Basic earnings per share from continuing operations was CNY 0.0061 compared to basic loss per share from continuing operations of CNY 0.0091 a year ago.
JIANGSU SIHUAN BIOENGINEERING CO., LTD is a China-based company principally engaged in the research, development, manufacture and distribution of medicines and health supplements. The Companyâs main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The Company is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The Company distributes its products in domestic market and to overseas markets.
JIANGSU SIHUAN BIOENGINEERING CO., LTD 
